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Abstract
Background: While non-invasive prenatal testing (NIPT) for fetal aneuploidy is commercially available in many
countries, little is known about how obstetric professionals in non-Western populations perceive the clinical
usefulness of NIPT in comparison with existing first-trimester combined screening (FTS) for Down syndrome (DS) or
invasive prenatal diagnosis (IPD), or perceptions of their ethical concerns arising from the use of NIPT.
Methods: A cross-sectional survey among 327 obstetric professionals (237 midwives, 90 obstetricians) in Hong Kong.
Results: Compared to FTS, NIPT was believed to: provide more psychological benefits and enable earlier consideration
of termination of pregnancy. Compared to IPD, NIPT was believed to: provide less psychological stress for high-risk
women and more psychological assurance for low-risk women, and offer an advantage to detect chromosomal
abnormalities earlier. Significant differences in perceived clinical usefulness were found by profession and healthcare
sector: (1) obstetricians reported more certain views towards the usefulness of NIPT than midwives and (2)
professionals in the public sector perceived less usefulness of NIPT than the private sector. Beliefs about earlier
detection of DS using NIPT were associated with ethical concerns about increasing abortion. Participants believing that
NIPT provided psychological assurance among low-risk women were less likely to be concerned about ethical issues
relating to informed decision-making and pre-test consultation for NIPT.
Conclusions: Our findings suggest the need for political debate initially on how to ensure pregnant women accessing
public services are informed about commercially available more advanced technology, but also on the potential
implementation of NIPT within public services to improve access and equity to DS screening services.
Keywords: Non-invasive prenatal test, Cell-free fetal DNA, Clinical decision-making, Attitude, Ethical concern,
Informed consent, Down syndrome, Hong Kong
Background
Non-invasive prenatal testing (NIPT) for Down syndrome
(DS) using cell-free DNA in maternal plasma (cff-DNA) is
now commercially established [1–3], and available in
many countries [4]. NIPT is considered a highly accurate
screening test for DS as it has a sensitivity rate of 99.2%
and false-positive rate (FPR) of 0.09% [5], compared with
conventional first-trimester combined screening (FTS,≈
90%, and 3.4%–5.4% respectively) [6]. Therefore, using
NIPT reduces the need for invasive prenatal diagnostic
tests (IPD - chorionic villus sampling (CVS) or amniocen-
tesis), which carry a procedure risk of miscarriage ranging
from 0.1–0.2% [7]. NIPT is not considered a diagnostic
test because it has a positive predictive value (PPV) of less
than 100% [6], occasionally giving non-reportable or false-
positive/negative results [8, 9]. Therefore, it is considered
to be a screening test, where a positive result requires con-
firmatory diagnostic testing [10, 11]. Like other countries
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in much of the world, antenatal testing is a routine part of
pregnancy care in Hong Kong (HK), where every pregnant
woman is offered blood tests and ultrasounds to evaluate
the fetus’ conditions. Women at increased risk after
screening (adjusted term risk of 1 in 250 or higher) are
counselled regarding their available options, including a
free of charge IPD in public hospitals or self-financed IPD
or NIPT from private obstetricians.
It is well recognised that in addition to the clinical val-
idity of NIPT, its implementation into public maternity
services and the development of national/local guide-
lines should be based on key stakeholders’ views, par-
ticularly ethical, legal and social implication (ELSI) [12].
There is much research on stakeholders’ views [13, 14],
generally showing that health professionals have a posi-
tive attitude towards implementing NIPT, but also some
important ethical concerns and diverse views about how
it should be implemented. For example, an American
study among obstetricians reported diverse views about
whether NIPT should be implemented as a primary or
secondary screening test, and whether it should be of-
fered to all or high-risk women [15].
Perception of implementing NIPT in public maternity
services is likely to be context-specific [16]. For example,
there has been a trend for rising maternal age at child-
birth in HK. The local population-wide census reports
that 70% of married women had their first baby during
the first 3 years of marriage, with 28.9 as the median age
of first marriage, and additionally reports one of the low-
est fertility rates in the world at 1.04 per women [17].
Parents in HK prefer to have one or two children at
most, partly for economic reasons [18], and regard hav-
ing a baby with chromosomal abnormalities to be a sig-
nificantly more negative lifetime event than a procedure-
related loss of an unborn baby [19, 20]. Accordingly,
local studies reported high rates of DS screening uptake
of 96.7% [20–22] and termination of 93.5% (29/31),
where 29 out of 31 women with a pregnancy with
chromosomal abnormalities, confirmed by karyotyping,
decided to undergo termination of pregnancy (TOP); the
remaining three cases underwent spontaneous miscar-
riage [22]. Similar to other studies [23], parents in HK
are highly likely to want reassurance that their unborn
baby will not have preventable genetic conditions. Ob-
stetric professionals in HK are likely to be aware of these
trends in fertility and societal preferences for a ‘normal’
baby and, therefore, feel more pressure to ensure that
women are offered the most appropriate technology as
early as possible in pregnancy.
Most of the research on different stakeholders’ views
of NIPT, however, has been conducted in Western popu-
lations, and the views of non-Western stakeholders are
rarely sought. The aim of the present study was to ex-
plore the views of obstetric professionals in HK about
(1) the clinical usefulness of NIPT in comparison with
current DS screening and diagnostic practice, and (2)
ethical concerns likely to arise from the use of NIPT.
Methods
Study settings
In HK, a 1st or 2nd trimester DS screening test has been
offered to pregnant women in public hospitals (hence free
of charge) since July 2010. Women can also opt for a
range of prenatal tests privately. Overall, women are free
to choose public and/or private sector services. Women
considering screening at public and private institutions
are provided with information about DS screening (e.g.,
pamphlets and videos), but are not ‘counselled’. Women
identified at increased risk following screening (adjusted
term risk of 1 in 250 or higher) in public services are
counselled about subsequent options and informed about
the availability of a free of charge IPD at the public hos-
pital, and privately available IPD and NIPT [24].
Recruitment of participants
Obstetricians, nurses and midwives providing FTS for DS
in HK at the time of the study, practising in the public
and/or private sector, were recruited during October 2013
to January 2014. All obstetricians listed on the HK Med-
ical Council Registry were sent the study information
sheet and questionnaire by post. Two reminders were sent
to non-respondents at the three-week interval after the
initial mailing. The response rate for the obstetricians was
27.2% (90/331). Midwives and nurses were recruited at
hospitals (n = 15; 4 public and 11 private) and private
clinics (n = 132) after obtaining approval from the respect-
ive departmental head of each institution. A written in-
formed consent was obtained. A total of 279 surveys were
delivered and 237 were collected, giving a response rate of
237/279 (84.9%). The overall response rate for the study
was 53.6% (327/610). Ethical approval was granted by the
University ethics committee.
Data collection
A self-completion questionnaire was developed by a
multidisciplinary group of clinicians and social scientists,
based on a review of the ELSI literature on NIPT. The
questionnaire was piloted with 5 obstetricians and 5
midwives to check content validity and preliminary psy-
chometric properties. Based on the results of this pilot,
minor changes were made before distribution. The ques-
tionnaire started with a brief description of NIPT, stating
that NIPT had been available commercially in HK since
December 2011 to detect chromosome aneuploidy (e.g.
Down syndrome) from 10 weeks of gestation, with a
sensitivity and specificity rate of over 99% and false-
positive rate of 0.1%. The questionnaire then consisted
of two parts to explore participants’ views about NIPT.
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Part one covered respondents’ perceptions of the clinical
usefulness of NIPT. Respondents were asked to compare
NIPT with (a) current DS screening (FTS) and then (b) in-
vasive prenatal diagnostic (IPD) tests by indicating their
agreement, disagreement or uncertainty (ticking ‘yes’, ‘no’
or ‘don’t know’, respectively) for 6 descriptive statements
about NIPT that were the most frequently mentioned
NIPT test characteristics and advantages among stake-
holders in Western studies. An additional statement was
added in the IPD section to assess perceived procedural
safety. The reliabilities of the measure in the study sample
were assessed by internal consistency, that is correlations
between items, and found be to be very good (Cronbach
alpha = .84 for FTS and alpha = .86 for IPD). Part two
covered perceptions of the ethical concerns likely to arise
from the use of NIPT, using a 5-point Likert scale (1 = not
at all concerned to 5 = extremely concerned), with 12
items categorized into four domains: (1) physician compe-
tency (two items; ‘lack of prior consultation about how
NIPT is provided’ and ‘NIPT performed when physicians
have inadequate knowledge’); (2) informed choice (two
items; ‘women undertake NIPT without careful informed
choice’ and ‘NIPT is performed when pregnant women
have inadequate information’); (3) accessibility (four items;
‘NIPT will develop into mass routine screening’, ‘unneces-
sary prenatal testing performed among low-risk women’,
‘more pregnant women would undergo multiple screening
tests’, and ‘unequal access to NIPT due to higher out-of-
pocket expense’); and (4) social implications (four items;
‘NIPT can lead to discrimination against newborns with
DS’, ‘abortion would become more prevalent’, ‘patients will
have limited autonomy to have a baby with DS’ and ‘NIPT
will develop in favor of non-medical purposes’). The
measure was reliable (Cronbach alpha = .89).
Data analysis
Chi-square and t-test were used to compare group
differences. Kruskal-Wallis test was used to compare
the relationship between the measures of ‘clinical use-
fulness’ and ‘ethical concerns’. To derive stable regres-
sion models with appropriate distributions, socio-
demographic variables of education and religious af-
filiation were collapsed into dichotomous variables
and the 5-point scale (1 = not at all concerned,
2 = slightly concerned, 3 = somewhat concerned,
4 = moderately concerned, 5 = extremely concerned)
was regrouped into 3 categories (1 = not at all con-
cerned, 2 = slightly-somewhat concerned, 3 = moder-
ately-extremely concerned). Multiple ordinal logistic
regressions were used to examine independent predic-
tors for ‘ethical concerns’ controlling for the factors
significant at p < 0.2 in univariate analyses including
socio-demographic variables. Adjusted odds ratios
(AORs) with 95% confidence intervals (CIs) were
reported. AORs for factors related to ‘clinical useful-
ness’ were determined about respondents who indi-
cated they were ‘uncertain.’
Results
Sample characteristics
Three hundred and 27 respondents completed the ques-
tionnaire. Their age ranged from 20 to 78 years (M = 39.1,
SD = 12.1) and clinical experience ranged from 1 to 55 years
(M = 12.5, SD = 11.1). Most respondents were female
(86%) and had completed university-level or above educa-
tion (79%). Twenty-eight percent (n = 90) of the respon-
dents were obstetricians and 72% (n = 237) were midwives/
nurses. Forty-two percent of the respondents (n = 137)
worked in public hospitals. About one-third of respondents
described themselves as Christian, 6% as Buddhists and
58% as having no religious affiliation. There was no signifi-
cant difference between social-demographic and profes-
sional characteristics except that males were more likely
than females to be obstetricians (χ2 = 86.7, p < 0.001) and
have completed university education (χ2 = 5.34, p = 0.031).
Perceptions of NIPT in comparison with first-trimester
combined screening (FTS)
Figure 1 shows respondents’ perceived clinical usefulness
of NIPT compared with FTS. Respondents believed
NIPT was likely to result in less psychological stress for
high-risk women (69%) and more psychological assur-
ance for low-risk women (67%). About 64% considered
the availability of the test as early as the first-trimester
was considered a favourable quality of NIPT. About half
of the respondents believed that NIPT results were eas-
ier to understand (50%) and that NIPT enabled earlier
consideration of TOP (53%). While 38% of the respon-
dents believed NIPT resulted in less maternal stress in
case of TOP, most respondents were unsure (42%).
Overall, the responses show that obstetricians had more
formed views on the usefulness of NIPT compared with
FTS (see Table 1). For example, their response of “don’t
know” to the items ranged from 3% to 9% (median = 5%,
M = 5%, SD = 2%), compared to midwives’ that ranged
from 11% to 28% (median = 19%, M = 20%, SD = 5.6%).
Furthermore, significant differences were found between
respondents by profession and healthcare sector, but not
education. Professionals working in public hospitals were
more likely than those in private hospitals to believe that
NIPT was as useful as FTS on psychological benefits in
terms of reduction of maternal stress relating to pregnancy.
Comparisons of NIPT with invasive prenatal diagnosis
(IPD)
Figure 2 shows respondents’ perceived clinical usefulness
of NIPT compared with IPD. Respondents believed
NIPT was likely to result in less psychological stress for
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high-risk women (79%) and more psychological assur-
ance for low-risk women (69%). About 63% considered
earlier detection of abnormalities as an advantage. Most
respondents were unsure (41%) or did not believe that
NIPT results were easier to understand than IPD. Fifty
percent of the respondents believed NIPT enabled earl-
ier consideration of TOP, although 33% were unsure.
Respondents were divided on whether NIPT did (41%)
or did not (41%) result in less maternal stress in case of
TOP. Most respondents (89%) also believed NIPT pro-
vided safer testing for the fetus than IPD.
Overall, the responses show that respondents with uni-
versity education had more formed views on the useful-
ness of NIPT (see Table 2), including its psychological
Fig. 1 Comparison of Perceived Clinical Utility of NIPT with First-trimester Combined Screening (FTS)
Table 1 Comparisons of Perceived Clinical Utility of NIPT with FTS by Demographic Characteristics
Total
(n = 327)
High
school
(n = 70)
University
(n = 257)
χ2 Obstetrician
(n = 90)
Midwife
(n = 237)
χ2 Public
Sector
(n = 136)
Private
Sector
(n = 191)
χ2
Less physiological stress for
high-risk women
Y 69% 69% 70% 5.80 68% 70% 4.85 61% 75% 7.24*
N 22% 15% 23% 28% 19% 29% 17%
DK 9% 16% 7% 4% 11% 10% 8%
Further psychological assurance
for low-risk women
Y 67% 67% 67% 4.63 82% 62% 16.6*** 61% 71% 6.67*
N 20% 13% 21% 13% 21% 26% 15%
DK 13% 20% 12% 5% 17% 13% 14%
Earlier detection of
chromosome abnormality
Y 64% 60% 65% 2.29 60% 65% 24.6*** 57% 69% 4.48
N 22% 20% 22% 37% 16% 25% 19%
DK 14% 20% 13% 3% 19% 18% 12%
Earlier consideration of
termination of pregnancy
Y 53% 49% 54% 2.30 52% 52% 10.5** 46% 58% 5.33
N 33% 31% 34% 42% 30% 40% 28%
DK 14% 20% 12% 6% 18% 14% 14%
Easier comprehension of test
result
Y 50% 46% 51% 4.91 58% 47% 22.7*** 44% 54% 6.53*
N 28% 23% 30% 37% 25% 36% 23%
DK 22% 31% 19% 5% 28% 20% 23%
Less maternal stress in case of
termination of pregnancy
Y 38% 44% 36% 5.18 34% 39% 15.9*** 28% 45% 10.4**
N 42% 30% 45% 57% 36% 50% 36%
DK 20% 26% 19% 9% 25% 22% 19%
Y = Yes; N = No; DK = Don’t Know. *p < .05; ** p < .01, *** p < .001
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Fig. 2 Comparison of Perceived Clinical Utility of NIPT with Invasive Prenatal Diagnosis (IPD)
Table 2 Comparison of Perceived Clinical Utility of NIPT with IPD by Demographic Characteristics
Total
(n = 327)
High
school
(n = 70)
University
(n = 257)
χ2 Obstetrician
(n = 90)
Midwife
(n = 237)
χ2 Public
Sector
(n = 136)
Private
Sector
(n = 191)
χ2
Safer testing for the fetus Y 89% 77% 93% 14.2** 96% 87% 4.94 93% 86% 4.89
N 4% 6% 4% 1% 5% 2% 6%
DK 7% 17% 3% 3% 8% 5% 8%
Less physiological stress for
high-risk women
Y 79% 69% 82% 13.6** 78% 80% 2.47 77% 81% 1.41
N 12% 10% 12% 16% 10% 14% 10%
DK 9% 21% 6% 6% 10% 9% 9%
Further psychological
assurance for low-risk women
Y 69% 64% 71% 3.33 68% 70% 12.8** 61% 75% 7.89*
N 20% 19% 20% 29% 16% 26% 15%
DK 11% 17% 9% 3% 14% 13% 10%
Earlier detection of
chromosome abnormality
Y 63% 59% 65% 8.03* 47% 70% 41.6*** 60% 66% 1.46
N 23% 17% 25% 48% 14% 25% 22%
DK 14% 24% 10% 5% 16% 15% 12%
Earlier consideration of
termination of pregnancy
Y 50% 49% 50% 7.78* 39% 54% 25.8*** 40% 57% 8.28*
N 33% 24% 36% 54% 26% 40% 29%
DK 17% 27% 14% 7% 20% 20% 14%
Less maternal stress in case
of termination of pregnancy
Y 41% 46% 39% 10.7** 32% 44% 27.9*** 32% 47% 8.03*
N 41% 26% 45% 62% 33% 48% 36%
DK 18% 28% 16% 6% 23% 20% 17%
Easier comprehension of test
result
Y 39% 49% 36% 21.6*** 18% 46% 65.0*** 30% 45% 11.6**
N 41% 19% 47% 77% 28% 52% 34%
DK 20% 32% 17% 5% 26% 18% 21%
Y = Yes, N = No, DK = Don’t Know
*p < .05; ** p < .01, *** p < .001
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benefits for high-risk women, comprehension of NIPT
result, and procedural safety. Regarding profession, the
pattern of significant differences was similar to that ob-
served when comparing NIPT with FTS. Obstetricians
were less likely than midwives to perceive that NIPT
was as useful as IPD on psychological benefits. Also,
professionals working in public hospitals were less likely
than those in private hospitals to believe that NIPT was
more useful than IPD for assuring low-risk women or
resulting in less maternal stress in cases of TOP.
Ethical concerns in the implementation of NIPT
The three issues of most concern to respondents
about NIPT were: more women would undergo mul-
tiple screening tests (44%); unequal access to NIPT
due to higher out-of-pocket expense (39%); and NIPT
being performed while women have inadequate infor-
mation (36%, see Fig. 3). The two items that respon-
dents were least concerned about (not at all or
somewhat-slightly concerned) were related to social
implications of NIPT, namely women would have lim-
ited autonomy to have a baby with DS (22%, 60%, re-
spectively) and NIPT can lead to discrimination
against new-borns with DS (24%, 61%, respectively).
Obstetricians were more concerned than midwives
about increasing uptake of NIPT without careful in-
formed choice (29% vs. 42%, p = 0.05) and less con-
cerned about increasing rates of abortion (33% vs.
14%, p < 0.001), women’s limited autonomy to have a
baby with DS (22% vs. 8%, p < 0.001), and increasing
discrimination of DS (18% vs. 6%, p < 0.001). Com-
pared with professionals in the private sector, those in
the public sector were more concerned about women
undergo multiple screening tests (38% vs. 52%,
p = 0.015), less concerned about increasing abortion
(32% vs. 23%, p = 0.021), unnecessary uptake of NIPT
among low-risk women (30% vs. 27%, p = 0.04), and
use of NIPT for non-medical purposes (34% vs. 32%,
p = 0.03) such as sex determination.
Associations between clinical validity, perceived utility
and ethical concerns
Table 3 shows multiple ordinal regressions of respon-
dents’ views about the clinical usefulness of NIPT and its
ethical implications on both univariate analysis and after
adjusting for confounding factors. Respondents believed
NIPT would result in less maternal stress in cases of
TOP and were concerned about women undertaking
multiple screening tests (AOR = 1.64). Respondents also
believed NIPT was useful in the early detection of DS,
but were concerned about increasing abortion rates for
both FTS (AOR = 1.62) and IPD (AOR = 1.59). In
addition, respondents believed NIPT could provide more
psychological assurance for low-risk women than IPD,
and had little concern about physicians’ lack of know-
ledge and skills in discussing NIPT with women
(AOR = 0.63), lack of consultation with women
(AOR = 0.51), and women undertaking the test without
careful informed choice (AOR = 0.48). In contrast, re-
spondents believed NIPT could provide a similar level of
assurance as IPD, were concerned about the lack of con-
sultation with women (AOR = 1.85) and women under-
taking the test without careful informed choice
(AOR = 2.16).
Fig. 3 Ethical Concerns in the Implementation of NIPT. Numbers in the bar indicate the percentages of responses. From left to right, 5-point Likert
scale is as follows: light grey = not at all concerned; grey = slightly-somewhat concerned; dark grey = moderately-extremely concerned
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Discussion
Overall, the obstetric professionals in our study believed
that compared with tests in the current screening pathway
in the public sector, the main usefulness of NIPT related
to psychological benefits. They believed it would result in
less stress in high-risk women and assurance in low-risk
women, although not less stress in women considering
TOP. The perceived psychological benefits may be due to
the better sensitivity of NIPT [25], hence more acceptance
of high-risk test result. However, despite perceived clinical
usefulness of the test, the uncertainty and anxieties associ-
ated with unforeseen pregnancy outcomes relate to beliefs
that TOP was likely to be stressful for women irrespective
of the technology used. These findings reinforce that while
newer, improved technology may be useful in alleviating
some psychological implications of screening tests, obstet-
ric professionals should provide pre-test information/
counselling to ensure that women opting for screening
tests for psychological assurance are aware of the psycho-
logical implications of a high-risk screening result, includ-
ing decisions about TOP.
Diverse opinions about the clinical usefulness of NIPT
by profession and healthcare sector suggest that clinical
integration of the test to existing screening and diagnosis
pathway remains in its infancy [14, 26]. Obstetricians
had more formed views than midwives about the useful-
ness of NIPT, and the findings suggest that they believed
NIPT was more useful than FTS, but not necessarily
Table 3 Multiple Ordinal Regressions of Perceived Clinical Utility of NIPT for Ethical Concerns
Abortion would
become more
prevalent
Patients will
have limited
autonomy to
have a baby
with Down
syndrome
NIPT can lead to
discrimination
against
newborns with
Down
syndrome
Testing
performed
when physicians
have inadequate
knowledge of
NIPT
Lack of prior
consultation
about how NIPT
is provided and
performed
Increase in
women’s
undertaking
NIPT without
careful informed
choice
More pregnant
women would
undergo
multiple
screening tests
AORa (95%CI) AORa (95%CI) AORa (95%CI) AORa (95%CI) AORa (95%CI) AORa (95%CI) AORa (95%CI)
Comparison of NIPT with FTS
Easier
comprehension
of test result
Y 1.04 (0.68–1.58) 1.12 (0.72–1.73)
N 0.72 (0.45–1.14) 0.72 (0.44–1.16)
Earlier detection
of chromosome
abnormality
Y 1.62 (1.04–2.51)*
N 0.57 (0.34–0.97)*
Earlier
consideration of
termination of
pregnancy
Y 1.19 (0.78–1.82)
N 1.45 (0.93–2.27)
Less maternal
stress in case of
termination of
pregnancy
Y 0.94 (0.61–1.45)
N 1.64 (1.06–2.54)*
Comparisons of NIPT with IPD
Earlier detection
of chromosome
abnormality
Y 1.59 (1.02–2.48)* 1.10 (0.70–1.72) 0.81 (0.49–1.33)
N 0.56 (0.34–0.94)* 0.64 (0.38–1.08) 0.94 (0.53–1.69)
Easier
comprehension
of test result
Y 1.11 (0.72–1.72) 0.91 (0.58–1.42) 0.82 (0.49–1.37)
N 0.51 (0.33–
0.79)**
0.69 (0.43–1.10) 0.89 (0.52–1.51)
Higher
sensitivity
Y 0.98 (0.63–1.53) 1.37 (0.87–2.17) 0.92 (0.55–1.55)
N 0.59 (0.38–0.92)* 0.52 (0.32–0.84)** 0.75 (0.44–1.27)
Further
psychological
assurance for
low-risk women
Y 0.63 (0.40–0.99)* 0.51 (0.31–0.82)** 0.48 (0.29–0.81)**
N 1.34 (0.79–2.28) 1.85 (1.07–3.19)* 2.16 (1.21–3.87)**
Earlier
consideration of
termination of
pregnancy
Y 1.29 (0.82–2.05)
N 1.13 (0.70–1.85)
Y = Yes, N = No, DK = Don’t Know (reference group)
*p < .05; ** p < .01, *** p < .001
aadjusted for demographics variables, including age, gender, religion, profession, highest education, place of work, years of experience
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more useful than IPD. This is most likely due to NIPT
being a highly accurate test, but is a screening test at
best and not diagnostic. Furthermore, in relation to dif-
ferences about ethical issues, obstetric professionals in
the public sector were more concerned than those in the
private sector about women undergoing multiple screen-
ing tests. This may be because they perceive few benefits
in multiple screening tests and, therefore, may poten-
tially withhold information about NIPT [27]. These find-
ings suggest the need for guidelines in public hospitals
about whether and how women should be informed
about NIPT, and that any information provided clarifies
that NIPT is a screening test.
Obstetric professionals in public hospitals reported
more conservative views than those in the private sector,
suggesting that NIPT was equivalent to FTS. Such a differ-
ence in views may result in a lack of referral by obstetric
professionals in public setting to NIPT that is currently
only available commercially. HK is a pioneering region for
the development and implementation of NIPT in ante-
natal care, where pregnant women are exposed to infor-
mation about NIPT through various media channels [28,
29]. Informing women identified at high-risk via FTS in
the public sector about NIPT could ensure that they re-
ceive similar information to women in the private sector,
although consideration should also be given to the ethical
implications of raising awareness about a test in women in
the public sector unable to afford it. Therefore, there is a
need for debate and the development of guidelines for ob-
stetric professionals in public hospitals on whether NIPT
should be an option presented to high-risk women during
counselling, and the extent to which this relates to
women’s autonomous decision-making.
Our findings are important for informing current de-
bates globally as to whether NIPT should be introduced as
a primary screening test. Obstetric professionals believed
the use of NIPT would enable early detection of the fetus’s
condition, which was important for reassuring women,
and because early detection may result in women experi-
encing less physically/psychological burden due to earlier
consideration of selective abortion [28]. These findings
suggest obstetric professionals’ preference for earlier
screening and diagnostic tests to enable early selective
abortion. However, any policy/clinical consideration of
implementing NIPT as early as possible along the ante-
natal screening pathway, say as a primary screening test,
would also need to take into account the implications of
using an earlier IPD procedure, i.e. CVS at 10-13th weeks
of gestation. This is because CVS has an increased risk for
fetal loss compared with amniocentesis [30, 31]. Further-
more, amniocentesis is preferable over CVS to avoid du-
plicating the original placental mosaicism that resulted in
primary NIPT screening result: both CVS and NIPT may
be then misleading when there is confined placental
mosaicism [32]. The extent to which obstetric profes-
sionals and pregnant women are aware of the increased
risk of CVS as an earlier diagnostic test (to complement
the earlier NIPT test) in comparison to amniocentesis is
not known, and the extent to which this increased risk
would influence obstetric professionals’ or women’s pref-
erences for the type of screening test, subsequent diagnos-
tic test, or timing of these test needs further research.
Half of the respondents in the present study believed
that NIPT results were not easier for them to understand
than FTS. Reporting formats of NIPT results vary across
laboratories and most in HK present results in categories
(i.e., either yes/no or positive/negative). Perhaps obstetric
providers not only need to understand the mechanism of
how cff-DNA sequencing technology yields higher analyt-
ical validity yet not performed as confirmatory testing
[33], but also need to be aware of the differences between
information reported by individual NIPT laboratories and
the potential validity of patients’ result. Currently, the
present fetal fraction is not universally reported, where ob-
stetric professionals must accept NIPT results at a face
value and assume that there was adequate DNA of fetal
origins present [34]. A platform supporting education ini-
tiatives for obstetric professionals is essential, firstly, to en-
sure that they understand various ways in which
laboratories may report NIPT results, understand their
implications for pregnant women, and how best to com-
municate these results to women and secondly to ensure
women are fully informed about the test.
Similar to our study, recent studies in the UK and US
report favourable attitudes towards NIPT over conven-
tional DS screening among obstetric professionals mainly
due to clinical advantages [35, 36]. It is important to note
that the obstetric professionals in our study, who believed
NIPT was a more useful test than FTS and IPD, expressed
less ethical concerns than those who were uncertain about
NIPT test characteristics. These findings suggest the need
for a balanced approach to training obstetric professionals
about NIPT. That is, while better knowledge of NIPT
could alleviate obstetric professionals’ uncertain ethical
concerns, they need to be aware of women’s need for pre-
and post-test consultation on NIPT ensuring that women
are making informed reproductive choices. Prenatal
screening providers’ limited familiarity and experience
with NIPT and limited resources to assist with counselling
were common barriers encountered when providing
women with counselling about NIPT [37], highlighting
the unmet services needs in providing pre- and post-test
information on the clinical usefulness and limitations of
NIPT [38–40]. Practice guideline for obstetric profes-
sionals in both private and public sectors should set out
the need for the provision of pre- and post-NIPT informa-
tion needs to ensure the provision of a service that meets
women’s need for information.
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The finding of positive associations of further psycho-
logical assurance in low-risk women with ethical concerns
about physician competency (inadequate knowledge of
NIPT and lack of prior consultation about how NIPT) and
‘increase of undertaking NIPT without informed choice’
further suggest the need for debate and development of
guidelines on whether and how NIPT should be men-
tioned by obstetric professionals on the current DS
screening pathway in public hospitals. This is particularly
important in light of our previous research showing that
women screened low-risk following FTS preferred to use
NIPT as means of “buying another insurance” to confirm
a previously received negative test result in pregnancy care
[28]. Women’s preferences for NIPT may be affected by
how and what information they receive from various
sources ranging from lay-media, social influence, and pro-
fessional opinions [28, 41]. Unlike Western contexts, there
is a need for post-test counselling for low-risk women to
enable better decision-making about further tests, because
they are likely to undertake multiple DS screening tests,
both FTS and NIPT, for psychological assurance despite
the absence of an indication of a fetal anomaly [28].
The perceived usefulness compared with FTS and IPD
was not associated with the item on the ethical concerns
addressing public health implications of NIPT, including
an increase of mass routine screening, unequal access to
NIPT due to high cost, and development of NIPT for
non-medical purposes. It appears that these concerns are
independent of how NIPT is perceived in comparison
with FTS and IPD. Possible explanations would be, as
stated earlier, HK provides universal DS screening for
women irrespective of age and the scale-up rates of FTS
were already high, over 90% [21]. Clinical adoption of
NIPT might not affect the rate of routine screening in
HK. The concerns about a high-cost private test and non-
medical use of NIPT have little to do with a comparison
of usefulness with existing prenatal testing for DS.
This was a cross-sectional study in a specific population,
which inevitably reduces the confidence with which the
findings can be generalised. However, the findings are
likely to be generalizable to other countries with similar
clinical contexts, such as those offering government
funded antenatal screening programmes for DS and likely
to consider the implementation of NIPT within this
screening pathway. Further research capturing the views
of obstetric professionals in other Eastern countries could
enhance our understanding of the ethical and social impli-
cation of NIPT in this part of the world. The lower re-
sponses rate among obstetricians compared to midwives
may have been due to the different recruitment strategies
adopted. Midwives were invited in person by a researcher,
while obstetricians were approached via a postal invitation
because of our assumption of their comparatively limited
time during work hours to discuss research participation.
A more personal approach to recruiting may have led to a
better participation rate of obstetricians. Qualitative re-
search approaches could provide a more in-depth under-
standing of the reasons for the views expressed by the
obstetric professionals in this study. Furthermore, research
is needed with a wider range of stakeholders, including
the views of service users and individuals responsible at a
policy level for commissioning, regulating and developing
guidelines for the use of genetic technologies. Neverthe-
less, our study highlights important points that could in-
form debates at policy level about the implementation of
NIPT within public services in HK and other countries.
Conclusions
With the trend for rising maternal age at childbirth and
lower fertility rates in many parts of the world, more
pregnant women are deemed high-risk for DS and,
therefore, likely to want to access NIPT as a preventive
measure. Meanwhile, more fetal conditions are likely to
be detected by NIPT using cff-DNA sequencing in prac-
tices. Our findings highlight the educational and training
needs of obstetric professionals, the need for policy de-
bates on the potential implementation of NIPT within
public services, and an urgent need for the development
of a standard care guideline on how to ensure pregnant
women who use public antenatal services are informed
about commercially available more advanced prenatal
technology.
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